COMPANY

SciTech Development

HQ: Grosse Pointe Farms, MI source · scitechdevelopment.com ↗ · Midwest

Keywords: drug delivery oncology cancer T-cell non-Hodgkin lymphoma primary cutaneous T-cell non-Hodgkin lymphoma T-cell Lymphoma Cutaneous/Peripheral T-Cell Lymphoma Peripheral T-cell Lymphoma Not Classified Peripheral T-Cell Lymphoma Primary Cutaneous T-cell Lymphoma Unspecified Cutaneous T-Cell Lymphoma Cutaneous T-cell Lymphoma Follicular T-Cell Lymphoma Angioimmunoblastic T-cell Lymphoma Sézary's Disease Mycosis Fungoides Small Cell Lung Cancer Fenretinide

Location: Grosse Pointe Farms, MI · source · Oct 15, 2026

Profile checked Oct 10, 2026

2Trials (company is sponsor)8NIH grants

Timeline

Dec 11, 2025 Trial start 1: Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer source ↗
Dec 18, 2023 Trial start 1: Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma source ↗

Upcoming milestones

May 1, 2027 (ESTIMATED) · 1 · Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer · NCT06922539
Jun 1, 2028 (ESTIMATED) · 1 · Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma · NCT04234048

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT04234048	Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma	1	Recruiting	Dec 18, 2023	Jun 1, 2028 (estimated)
NCT06922539	Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer	1	Recruiting	Dec 11, 2025	May 1, 2027 (estimated)

NIH awards 8

Annual award amounts. Total $2.6M.

Sep 15, 2005 NIH award 5R41CA101681-02 FY2005: $238,530 awarded for that fiscal year; activity R41 (STTR); PI HOLSAPPLE, EARLE; recipient as written: SCITECH DEVELOPMENT, LLC, GROSSE POINTE FARMS, MI. In Vitro Cardiac Device for source ↗
Apr 1, 2005 NIH award 5R44CA093115-03 FY2005: $1,077,580 awarded for that fiscal year; activity R44 (SBIR); PI HOLSAPPLE, EARLE; recipient as written: SCITECH DEVELOPMENT, LLC, GROSSE POINTE FARMS, MI. Parenteral Formulations fo source ↗
Sep 21, 2004 NIH award 1R41CA101681-01A1 FY2004: $239,947 awarded for that fiscal year; activity R41 (STTR); PI PARCHMENT, RALPH E; recipient as written: SCITECH DEVELOPMENT, LLC, GROSSE POINTE FARMS, MI. In Vitro Cardiac Device source ↗
Apr 30, 2004 NIH award 1R43CA108072-01 FY2004: $140,800 awarded for that fiscal year; activity R43 (SBIR); PI LITTRUP, PETER J; recipient as written: SCITECH DEVELOPMENT, LLC, GROSSE POINTE FARMS, MI. Clinical Breast Ultrasound T source ↗
Apr 29, 2004 NIH award 1R43CA107910-01 FY2004: $144,629 awarded for that fiscal year; activity R43 (SBIR); PI LITTRUP, PETER J; recipient as written: SCITECH DEVELOPMENT, LLC, GROSSE POINTE FARMS, MI. Dynamic Focusing for Non-Inv source ↗
Mar 29, 2004 NIH award 2R44CA093115-02A1 FY2004: $507,307 awarded for that fiscal year; activity R44 (SBIR); PI PARCHMENT, RALPH E; recipient as written: SCITECH DEVELOPMENT, LLC, GROSSE POINTE FARMS, MI. Parenteral Formulations source ↗
Sep 19, 2001 NIH award 1R43CA093115-01 FY2001: $154,471 awarded for that fiscal year; activity R43 (SBIR); PI PARCHMENT, RALPH E; recipient as written: SCITECH DEVELOPMENT, LLC, GROSSE POINTE FARMS, MI. Parenteral Formulations fo source ↗
Aug 31, 2001 NIH award 1R43CA090088-01 FY2001: $139,508 awarded for that fiscal year; activity R43 (SBIR); PI PARCHMENT, RALPH E; recipient as written: SCITECH DEVELOPMENT, LLC, GROSSE POINTE FARMS, MI. STABLE STEREOISOMER ANALOG source ↗